Avita Medical Inc Revenue Growth Rates (RCEL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Avita Medical Inc   (NASDAQ: RCEL)
 

RCEL's Revenue Growth by Quarter and Year

Avita Medical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RCEL/growth
https://api.csimarket.com/api/v1/companies/RCEL/fundamentals
https://api.csimarket.com/api/v1/companies/RCEL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RCEL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 26.11
2nd Quarter June 21.70
1st Quarter March 19.25
FY 67.06

RCELs Annual Revenue
Avita Medical Inc 's Revenue in the fiscal year 2025 $ 71.61 millions
Avita Medical Inc 's Revenue in the fiscal year 2024 $ 64.25 millions
Avita Medical Inc 's Revenue in the fiscal year 2023 $ 50.14 millions
Avita Medical Inc 's Revenue in the fiscal year 2022 $ 34.42 millions
Avita Medical Inc 's Revenue in the fiscal year 2021 $ 29.23 millions




RCEL Revenue third quarter 2026 Y/Y Growth Comment
Avita Medical Inc reported Revenue rise of 53.07% year on year in the third quarter 2026, to $ 26.11 millions, this is lower than Avita Medical Inc 's recent average Revenue rise of 89.49%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 66 other companies have achieved higher Revenue growth. While Avita Medical Inc ' s Revenue jump of 53.07% ranks overall at the positon no. 1134 in the third quarter 2026.


RCEL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 53.07 %
2nd Quarter June 17.81 %
1st Quarter March 4 %
FY   -

Financial Statements
Avita Medical Inc 's third quarter 2026 Revenue $ 26.11 millions RCEL's Income Statement
Avita Medical Inc 's third quarter 2025 Revenue $ 17.06 millions Quarterly RCEL's Income Statement


RCEL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 20.34 %
2nd Quarter June 12.73 %
1st Quarter March 9.25 %
FY (Year on Year)   -


Back to RCEL Growth rate Comparisons >> Back to RCEL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #67
Healthcare Sector #217
Overall #1134

Revenue Y/Y Growth Statistics
High Average Low
1108.18 % 89.49 % -19.11 %
(Jun 30 2020)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #67
Healthcare Sector #217
Overall #1134
Revenue Y/Y Growth Statistics
High Average Low
1108.18 % 89.49 % -19.11 %
(Jun 30 2020)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Avita Medical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
286.62 % 22.68 % -31.87 %
(Dec 31 2018)  


RCEL's III. Quarter Q/Q Revenue Comment
Avita Medical Inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.34% quarter on quarter, to $ 26.11 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -7.38% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Avita Medical Inc 's Revenue growth quarter on quarter, overall rank is 711.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #711
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #711
Revenue Q/Q Growth Statistics
High Average Low
286.62 % 22.68 % -31.87 %
(Dec 31 2018)  


RCEL's III. Quarter Q/Q Revenue Comment
Avita Medical Inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.34% quarter on quarter, to $ 26.11 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -7.38% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Avita Medical Inc 's Revenue growth quarter on quarter, overall rank is 711.


Avita Medical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 84.68
Y / Y Revenue Growth (TTM) 16.97 %
Year on Year Revenue Growth Overall Ranking # 430
Seqeuential Revenue Change (TTM) 11.97 %
Seq. Revenue Growth (TTM) Overall Ranking # 2102


Cumulative Revenue growth Comment
Although Avita Medical Inc 's Annual Revenue growth year on year were below company's average 46.34% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.97% year on year, from 1% in Jun 30 2026.

In the Healthcare sector 107 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 309 to 430.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 115
Healthcare Sector # 108
Overall # 430

Revenue TTM Y/Y Growth Statistics
High Average Low
160.56 %
 46.34 %
0.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 115
Sector # 315
S&P 500 # 2102
Cumulative Revenue growth Comment
Although Avita Medical Inc 's Annual Revenue growth year on year were below company's average 46.34% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.97% year on year, from 1% in Jun 30 2026.

In the Healthcare sector 107 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 309 to 430.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 115
Healthcare Sector # 108
Overall # 430

Revenue TTM Y/Y Growth Statistics
High Average Low
160.56 %
46.34 %
0.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 115
Sector # 315
S&P 500 # 2102




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RCEL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions


About Avita Medical Inc Revenue Growth Rates (RCEL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Avita Medical Inc (CIK 1762303).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449873
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Avita Medical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.